Piper Sandler Maintains Overweight on ALX Oncology Holdings, Raises Price Target to $4
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst Allison Bratzel maintains ALX Oncology Holdings (NASDAQ:ALXO) with a Overweight and raises the price target from $3 to $4.
Piper Sandler analyst Allison Bratzel maintains ALX Oncology Holdings (NASDAQ:ALXO) with a Overweight and raises the price target from $3 to $4.